Clinical Trials Browser

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01884441 2014-01-29

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Phase 2 Unknown

59 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

NCT01649622 2012-11-08

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Phase 2 Withdrawn

37 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT00385125 2006-10-06

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase 2 Unknown

30 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Clinical Trials

TERZO

FIL_A-BEGEV

HL-R2-B2

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

BVR

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL